Seres Therapeutics Inc
$ 6.32
-2.62%
11 Jun - close price
- Market Cap 64,138,000 USD
- Current Price $ 6.32
- High / Low $ 6.80 / 6.26
- Stock P/E N/A
- Book Value 2.76
- EPS -5.20
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.39 %
- ROE -1.22 %
- 52 Week High 29.98
- 52 Week Low 6.01
About
Seres Therapeutics, Inc., a microbiome therapeutic platform company, is involved in the development of bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$22.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-03-12 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-03-13 | 2024-11-13 | 2024-08-13 | 2024-05-08 | 2024-03-05 | 2023-11-02 | 2023-08-08 |
| Reported EPS | -2.08 | -1.76 | 0.94 | -2.27 | -2.24 | -0.11 | -6.6 | -4.4 | -5.4 | -0.32 | -7.4 | 7.2 |
| Estimated EPS | -1.88 | -1.6 | 1.28 | -2.27 | 1.97 | -0.1993 | -0.04 | -5.91 | -7.25 | -0.5 | -10.65 | 10.97 |
| Surprise | -0.2 | -0.16 | -0.34 | 0 | -4.21 | 0.0893 | -6.56 | 1.51 | 1.85 | 0.18 | 3.25 | -3.77 |
| Surprise Percentage | -10.6383% | -10% | -26.5625% | 0% | -213.7056% | 44.8068% | -16400% | 25.5499% | 25.5172% | 36% | 30.5164% | -34.3665% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -2.3 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MCRB
2026-06-10 01:10:13
Seres Therapeutics is reducing its office space in Cambridge by more than half to preserve its cash reserves, aiming to extend its financial runway into 2027. This move comes as the biotech company faces a cash crunch. The company's decision involves significant real estate cuts to manage its operational costs.
2026-06-06 06:39:26
Seres Therapeutics has announced two key transactions to improve its financial position, including an amendment with Nestlé Health Science for a $25 million payout by buying out future VOWST net sales-based milestones and a restructured lease agreement to significantly cut ongoing facility costs. These actions are projected to extend the company's operating cash runway into the first quarter of 2027. The company aims to continue its focus on live biotherapeutic programs in inflammatory and immune diseases while seeking additional partnerships and capital.
2026-06-06 04:40:16
Seres Therapeutics (NASDAQ:MCRB) has secured a $25 million payment from Nestlé Health Science by amending their asset purchase agreement, effectively buying out future VOWST net sales-based milestones. This, along with a restructured lease agreement, is intended to strengthen Seres' balance sheet and extend its operating cash runway into Q1 2027. Despite a recent stock decline, an InvestingPro analysis suggests the stock may be undervalued.
2026-06-05 15:38:53
Seres Therapeutics has secured a $25 million deal with Nestlé Health Science for future milestone payments related to VOWST and restructured its corporate facility lease. These strategic financial moves are expected to extend the company's operating cash runway into the first quarter of 2027. The company is also preparing for a near-term clinical milestone with data from an investigator-sponsored study of SER-155.
2026-06-05 11:10:31
Seres Therapeutics has announced two transactions aimed at bolstering its financial position. These moves are designed to strengthen the company's balance sheet, significantly reduce ongoing lease costs, and extend its projected operating cash runway into the first quarter of 2027.
2026-06-05 11:10:31
Seres Therapeutics announced two transactions to bolster its financial position, including an agreement with Nestlé Health Science for a $25 million buyout of future VOWST™ sales-based milestones and a restructured lease. These actions are expected to extend the company's operating cash runway into Q1 2027 and materially reduce ongoing facility costs and long-term lease obligations. Additionally, the company anticipates clinical data this month from an investigator-sponsored study of SER-155.
